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Classical nuclear estrogen receptors (ER-␣) and progesterone receptors (PR) are expressed in vascular muscle cells (VMCs) (8-13, 14, 21) . The function of ovarian steroid hormone receptors in vascular muscle has recently received greater interest, in part, due to the heightened awareness of the cardioprotective effects of hormone-replacement therapy for postmenopausal women (20) .
Rhesus monkey coronary artery muscle cells identified as being positive for smooth muscle myosin heavy chain showed nuclear immunolabeling with PR and ER-␣ antibodies (14) . Pretreatment of these cells with 0.3-3 ng/ml progesterone or 3-100 pg/ml 17␤-estradiol for Ͼ24 h decreased the amplitude and duration of serotonin ϩ U-46619 (5-HTϩU)-stimulated intracellular Ca 2ϩ and protein kinase C (PKC) responses (14) . Modulation of VMC excitation-contraction signaling by estrogen and progesterone was blocked by ER-␣ and PR antagonists ICI-182780 and RU-486, respectively. This suggests that physiologically relevant concentrations of estrogen and progesterone reduce VMC reactivity via nuclear ER and PR signaling.
The mechanism by which estrogen and progesterone modulate VMC Ca 2ϩ and PKC responses to 5-HTϩU is not known but may involve modulation of thromboxane A 2 -receptor expression on the VMC membrane (15) . In addition, the relative degree of PR expression is decreased in the absence of 17␤-estradiol or presence of medroxyprogesterone acetate (MPA) (16) . MPA is a synthetic progestin commonly used in oral contraceptives and hormone-replacement regimens shown to negate the benefits of 17␤-estradiol, whereas bioidentical progesterone does not (16, 18, 19, 27) . Replacement of progesterone and/or 17␤-estradiol in ovariectomized (OVX) monkeys to levels observed before surgical menopause was shown to provide cardioprotection against 5-HTϩU-induced coronary artery vasospasm (5, 6, 16, 18) , suggesting that ovarian steroid hormones modulate coronary artery vasoconstrictor reactivity through classical nuclear steroid receptor signaling.
Chronic progesterone treatment reduces systemic blood pressure in humans (24) , and a membrane progesterone binding site was recently cloned from porcine coronary artery muscle cells (4), providing a possible basis for progesterone to mediate rapid effects on blood vessels. Thus, in the present study, we first examine the hypothesis that a 100-ng bolus of progesterone, administered by direct intracoronary injection during coronary ischemia, is capable of coronary vasodilation powerful enough to counteract vasospasm induced by a putative vasospasm stimulus combination, even in the presence of MPA. Second, we test whether estrogen or progesterone added directly to an agonist-stimulated isolated VMC in a form attached to albumin, which is believed to not rapidly cross the cell membrane and thus act extracellulary, would affect intracellular Ca 2ϩ and PKC signals.
METHODS
Animal model. OVX rhesus macaques (n ϭ 14; average age ϭ 13.3 Ϯ 0.7 yr; average weight ϭ 6.5 Ϯ 0.4 kg) were either not treated with steroids (control; n ϭ 6) or treated with 4 wk of estrogen in combination with a progestin for the last 2 wk, i.e., 17␤-estradiol and MPA (EM; n ϭ 6), 17␤-estradiol, progesterone, and MPA (EPM; n ϭ 1), or 17␤-estradiol and norethindrone (EN; n ϭ 1) via Silastic implants to achieve physiological levels of estrogen (60-120 pg/ml), progesterone (1-4 ng/ml), and therapeutic levels of MPA or norethindrone (0.5-2 ng/ml) (see Ref. 16 for further details). Monkeys reported herein are part of a larger study on the mechanism of coronary vasospasm and vascular muscle hyperreactivity. The epicardial coronary arteries in these monkeys showed hyperreactive responses to the vasoconstrictor challenges, which culminated in severe coronary constrictions that met the criteria for vasospasm. By definition, the criterion for coronary artery vasospasm is focal areas of severe constriction to less than one-third of the control diameter, followed by downstream dilation that persists for Ͼ5 min (6) . OVX monkeys treated with estrogen, progesterone, or estrogen ϩ progesterone, in previous studies, were not hyperreactive to the same coronary vasoconstrictor challenges and, with rare exception, did not meet the vasospasm criteria (16, 18) . Therefore, this report deals with a subset of monkeys in which we were able to evoke severe vasospasms, to which we applied progesterone or mibefradil and monitored the coronary diameter.
Coronary vasospasm provocation. The injection protocol employed for initiation of vasoconstriction, which appeared analogous to coronary vasospasm in humans, has been described previously (6, 16, 18) . The interventional challenge drugs, diluted in saline, were injected directly into the coronary artery as a 1-ml bolus over a 30-s interval. It is estimated that this results in an immediate 15-fold dilution of the syringe concentration in nonconstricted arteries (6) . In brief, the protocol is as follows. Rhesus monkeys were sedated with an intramuscular injection of ketamine (10 mg/ kg) at the radiology catheterization suite. For artery and venous catheterizations, 1-1.5% isoflurane in 70% O 2 and 30% nitrous oxide were continuously administered by inhalation to maintain a surgical plane of anesthesia. Blood pressure, electrocardiogram, heart rate, temperature, and percent O 2 saturation were continuously monitored and recorded. Before coronary catheterization, 1,000 units of heparin were administered intravenously. Control angiograms were acquired to document the anatomy of the epicardial coronary arteries by using a 1-to 2-ml injection of Hexabrix, a radiopaque contrast media. Angiograms were acquired immediately (within 15 s), at 3 min after each injection, and at later times when it was apparent that a persistent effect warranted additional images. Endothelial integrity was demonstrated by vasodilation with 1 M ACh, and intracoronary injection of 100 M serotonin (5-HT) was then used to show a lack of constriction in the large coronary arteries, due to an intact endothelium, or would detect endothelial defects as vasoconstriction if there was a site of artery damage. Next, coronary arteries were stimulated with 1 M U-46619 (U), a stable thromboxane A 2 mimetic. The next five injections constitute the main vasospasm challenges: three separate injections of combined 5-HT (100 M) and U (1 M), followed by the triple combination of 5-HT (100 M) and U (1 M) together with endothelin-1 (1 nM), and finally 5-HT (100 M) with a higher concentration of U (3 M). The vasospasm-like constrictions occurred after a cumulative total of 1-2 ng of U (5-HTϩU challenges 2 and 3 in most cases). If focal constrictions that meet the vasospasm criterion had not developed by the time cardiogenic shock was evident (diastolic blood pressure of Ͻ30 mmHg), the animal was termed "protected." We have shown that protection against vasospasm is strongly correlated with and probably is dependent on physiological levels of circulating estrogen and/or progesterone (16, 19) .
In this study, we tested the hypothesis that intracoronary injection of progesterone during an ongoing coronary artery vasospasm could relax the focal constriction and restore control diameter. Progesterone was diluted to 100 ng/ml in saline from a stock solution (1 mg/ml) in 100% ethanol (final concentration of ethanol ϭ 0.01%). There was no observed action of injection of 1 ml of vehicle. The intracoronary injection in 1 ml of progesterone was tested in six monkeys during an agonist-stimulated vasospasm, and coronary artery diameter was measured from angiograms taken 1, 3, 5, 10, 15, and 20 min later. Systolic and diastolic blood pressures were continuously recorded. For comparison, intracoronary administration of the Ca 2ϩ -channel blocker mibefradil (1 ml of 1 M) was also tested (n ϭ 6). Mibefradil is a novel T-type selective Ca 2ϩ -channel blocker (17) , which has previously been shown to relieve coronary artery vasospasm in monkeys (6, 16, 18) . On completion of the in vivo protocol, ketamine analgesia and tranquilization was reinstated, and the monkeys were taken to necropsy. The hearts were removed, and gross and histological examinations of the coronary arteries were conducted to determine whether there were indications of coronary artery disease (6) .
VMC preparation. OVX rhesus monkeys (n ϭ 6) were subjected to coronary artery vasospasm provocation challenges in a catheterization laboratory as described above. The epicardial coronary arteries in these groups showed hyperreactive responses to the vasoconstrictor challenges, which culminated in severe coronary constrictions that met the criteria for vasospasm in all six untreated OVX monkeys.
VMCs from the left anterior descending, circumflex, and right coronary arteries of six OVX monkeys were prepared as primary cell cultures (14, 19, 23) and used in experiments from day 3 to day 30 after isolation. These cells were never subcultured and maintained the characteristics of the source tissue, including contraction, relaxation, receptor integrity, and membrane electrical properties. Cells were dissociated with collagenase and protease enzymes in a potassium-glutamate (KG) solution that prevents loading with Na ϩ , Ca 2ϩ , or Cl Ϫ and results in a high proportion of viable, contracting cells (22, 25) . KG solution consists of (in mM) 140 potassium glutamate, 16 NaHCO3, 0.5 NaH2PO4, 30 HEPES, and 16.5 dextrose at pH 7.3. VMC was seeded at low density (small drop on each coverslip containing 10,000 cells/ml) in cardiovascular cell culture medium, fifth generation (CV5M) on 9 ϫ 22-mm or 20 ϫ 45-mm glass coverslips. After 72 h, cells were placed in a maintenance medium (CV5MM), which was replaced weekly. In CV5MM, the concentration of horse serum (HS) is reduced to 1.0%. CV5M contains MEM ϩ 10% HS, 1% L-glutamine, and 100 g/l ciprofloxicin. Phenol red was ex-cluded from all solutions because of known actions on estrogen receptors (1) .
VMC reactivity. To assess vascular reactivity, measurements of intracellular free Ca 2ϩ and PKC fluorescence intensity and mobilization/translocation were made on monkey coronary artery VMC as previously described (14) (15) (16) 19) . Ca 2ϩ and PKC were studied in the same VMC by using double labeling with different wavelength fluophores and two fluorescence filter sets. The fluorescent Ca 2ϩ indicator fluo 3 acetoxymethyl ester (fluo 3; Molecular Probes) was used to sense Ca 2ϩ . Live cell measurements of PKC were made by using hypericin (LC Laboratories). The concentration range used to detect PKC in our experiments was 30-300 nM, which is 10-100 times less than the IC 50 (3.4 M) and below the threshold concentration for inhibition of purified PKC (400 nM) (26) .
The fluorescent Ca 2ϩ and PKC images, which provide sensitive measures of vascular reactivity, were made with very low light levels by using multiple layers of filtering and an ultra-high-sensitivity (photon counting) microchannel plate camera (19) . Data acquired with the Hamamatsu photon counting camera were controlled and processed with Image Pro software customized for our studies with Visual Basic using a Pentium PC and an Imagraph A-D acquisition card with PCI local bus. Live cell images acquired during 5-s exposures of a 60-min protocol were analyzed to determine Ca 2ϩ and PKC fluorescence intensity and distribution and to provide statistical analysis and look up table color mapping. Statistical analysis was performed by using ANOVA.
Ca 2ϩ fluorescence. VMC on small glass coverslips were placed in a 300-l laminar flow chamber (7) . Isotonic solution for mammals, second generation (ISM2), which contains (in mM) 100 NaCl, 4 NaHCO3, 0.5 NaH2PO4, 4.7 KCl, 1.8 CaCl2, 0.41 MgCl2, 0.41 MgSO4, 50 HEPES (pH 7.37 at 22°C), and 5.5 dextrose, was continuously washed over the cells (at 1 ml/min) to facilitate equilibration and washout of stimuli. After a 15-min equilibration period in ISM2, VMCs were loaded at room temperature by adding 30 l of 1-10 M fluo3 for 15 min (into a total volume of ϳ300 l). VMCs were then washed for 5 min, and a time 0 (control) image was acquired. To the buffer directly above a VMC, 30 l of 10 M 5-HT plus 100 nM U was added. After 15 s under no-flow conditions, thus exposing the VMC to a final bath concentration of 1 M 5-HT ϩ 10 nM U, continuous flow of ISM2 at 1 ml/min was reinstated, the stimuli were washed out [half time (t 1/2) ϭ 30 s], and fluorescent Ca 2ϩ images were acquired at 1, 2, 5, 10, 15, 20, and 30 min by using a Zeiss Axiovert microscope with a C-Apochromat ϫ40, 1.2 numerical aperture confocal-design water-immersion objective. After the 30-min image was acquired, at which time the agonist-stimulated Ca 2ϩ responses were maximal, BSA-conjugated progesterone (P-BSA; final concentration ϭ 3 ng/ml) or BSA-conjugated 17␤-estradiol (E 2-BSA; 333 pg/ml) was added. After 1 min, flow of 1 ml/min was reinstated, and Ca 2ϩ images were acquired 3, 5, 10, 15, 20, 25, and 30 min later. Fluorescent Ca 2ϩ images (excitation filter, 487 nm; dichroic mirror, 505 nm; emission filter, 530 nm) for the whole cell thickness are expressed relative to the prestimulated basal level (percentage of control).
PKC. Hypericin was loaded for 5 min, and the excess indicator was washed out for 5 min (coinciding with the fluo 3 washout). By using the end of the 5-min washout as time 0, fluorescent PKC images were acquired immediately before 
-HTϩU. Additional PKC images were collected 5, 10, 15, 20, and 30 min after adding P-BSA or E 2-BSA. Hypericin fluorescent images were obtained with 5-s duration shuttered exposures with the following filters: 535 nm excitation, 560 nm dichroic mirror, and 570 nm long-pass emission filter. The whole cell fluorescence intensity was taken as an indication of the relative level of PKC in the VMC.
RESULTS
Coronary artery angiograms in hyperreactive female rhesus monkeys showed focal constrictions with an intracoronary injection of 1 ml of 100 M 5-HT ϩ 1 M U. These focal constrictions were relieved by intracoronary progesterone injection. A rapid and therefore putatively nongenomic action of progesterone on primate coronary arteries was observed. Progesterone actions were seen within minutes of intracoronary injection of 100 ng of the bioidentical hormone applied to severely constricted coronary arteries. Relaxation in response to progesterone was observed within about the same time frame as vasorelaxation by mibefradil, a selective Ttype Ca 2ϩ -channel blocker. Thus progesterone may act as a direct vasodilator to relieve even severe focal coronary artery constrictions in non-human primates. Figure 1 , a-d, shows example angiograms of the epicardial coronary arteries of an OVX monkey (Fig.  1a) in which focal constrictions of hourglass shape, as found in human coronary artery vasospasms, were induced and sustained at 5, 10, and 20 min (Fig. 1, b-d,  respectively) . Spontaneous relaxation of focal constrictions was observed only rarely, including in this example, as shown in Fig. 1e . Rather, coronary vasospasms in monkeys characteristically persisted for Ͼ20 min in arteries in which no vasodilator was given. Focal constrictions were reinitiated at the same anatomic point with a subsequent injection of 5-HTϩU (Fig. 1f) . Constrictions to less than one-third of control average diameter () in a specific segment of an epicardial artery were dilated by direct injection of 100 ng progesterone (1 ml injected over 30 s, which would be diluted ϳ15-fold by the coronary circulation if and when blood flow was reinstated; Fig. 1, g and h) . Progesterone relieved vasospasm-like constrictions in six of six monkeys tested; the monkeys tested in this group were untreated OVX (n ϭ 3) or OVX treated for 2 wk with EM (n ϭ 2) or EPM (n ϭ 1). This response began in the most rapid instances as early as the first measurement after progesterone administration (15 s later) when the radiopaque contrast media was injected. By 3 min after injection of progesterone, at the site of focal constrictions increased dramatically and significantly. Average preconstriction vs. 3 min after injection of progesterone showed a return to control, i.e., diameters were not significantly different ( Fig.  2A) . Completely restored were observed in monkeys over times ranging between 1 and 20 min after progesterone injection (means Ϯ SE ϭ 8.2 Ϯ 2.6 min).
Intracoronary injection of the Ca 2ϩ antagonist mibefradil (1 M) during an ongoing coronary artery vasospasm in six hyperreactive rhesus monkeys rapidly relieved the focal constrictions in every case (Fig. 2B) ; the monkeys tested in this group were untreated OVX (n ϭ 1) or OVX treated for 2 wk with EM (n ϭ 4) or EN (n ϭ 1). The average time required to relieve spasms with mibefradil was 3.3 Ϯ 0.6 min, which tended to be more rapid but was not statistically different than that observed with progesterone injections. Example angiograms, showing a similar time course of vasospasm relief by mibefradil and progesterone, are shown in Fig. 3. In Fig. 3, a-d , 5-HTϩU caused a focal constriction (vasospasm), as defined by the hourglass-shaped reduction in coronary artery diameter, to 25% (3,b and c) of the control diameter (3a) in an untreated OVX monkey. Mibefradil (Ro-40-5967, 1 M), injected at 1 ml/30 s, restored the diameter to 87.5% of the control diameter (Fig. 3d ) by 3 min after the intracoronary injection. Similarly, coronary artery angiograms in an Fig. 2 . Average diameter () of coronary arteries measured during a SϩU-induced spasm (focal constriction to Ͻ30% of control diameter that persisted for more than 5 min; SϩU constriction) was significantly reduced compared with the of arteries measured during a control Hexabrix injection (control). A: administration of 100 ng of progesterone (P; 1 ml injected over 30 s) resulted in rapid vasorelaxation at the site of the focal constriction, as shown by measured 3 min after injection of P (P 3Ј ). After an average of 8.2 Ϯ 2.6 min after injection of P (n ϭ 6), the focal constrictions had fully relaxed to their preconstriction diameters (P max ). B: administration of 1 M mibefradil (Ro40) injected over 30 s resulted in rapid vasorelaxation at the site of the focal constriction, as shown by measured 3 min after injection (Ro40 3Ј ). After an average of 3.3 Ϯ 0.6 min after injection of mibefradil (n ϭ 6), the focal constrictions had fully relaxed to their preconstriction diameters (Ro40 max ). Values are means Ϯ SE. NS, not different from control. *P Ͻ 0.05 vs. other groups.
EPM-treated OVX rhesus monkey showed focal constrictions on stimulation with 5-HTϩU and relief by progesterone. Figure 3 , d-g, shows the control (prestimulated) angiogram of the left anterior descending coronary artery (Fig. 3e) , followed by angiograms taken 3 ( Fig. 3f) and 15 min (Fig. 3g) after intracoronary injection of 5-HTϩU. The arrows in Fig. 3 , f and g, point to the site of focal constriction at which the diameter of the artery decreased from 2.0 to 0.1 mm. Direct injection of 100 ng of progesterone relieved the vasospasm beginning within 3 min (diameter ϭ 1.75 mm; Fig. 3h ) and completely restored the prestimulated diameter (2.0 mm) by 5 min (not shown). Similar results were observed when nifedipine, an L-type Ca 2ϩ -channel blocker, or nitroglycerin, a source of nitric oxide, were injected during vasospasm (data not shown). Electrocardiogram correlates of the severe vasoconstrictions manifested themselves as 1-to 3-mm elevations in ST segments and enlarged or inverted T waves. Intracoronary progesterone or mibefradil infusion during the severe, persistent focal coronary constrictions led to normalization of electrocardiogram abnormalities with approximately the same time course as the increase in coronary artery diameter.
As a separate in vitro correlate, we tested whether physiologically relevant levels of membrane-impermeant albumin-conjugated ovarian steroid hormones would modulate 5-HTϩU-stimulated VMC Ca 2ϩ and PKC responses. Maximum Ca 2ϩ levels were achieved 30 min after agonist stimulation in hyperreactive monkey VMC, at which time a final concentration of 333 pg/ml E 2 -BSA or 3 ng/ml P-BSA, both physiologically relevant concentrations, was applied to VMC. After 1 min, laminar flow of ISM2 at a rate of 1 ml/min was reinstated and fluorescent Ca 2ϩ and PKC images were acquired for an additional 30 min. Figure 4 shows the effect of P-BSA and E 2 -BSA on 10 M 5-HT ϩ 100 nM U stimulated intracellular Ca 2ϩ responses. Ca 2ϩ levels in VMC from OVX monkeys increased to 203 Ϯ 32% (n ϭ 5) and 250 Ϯ 34% (n ϭ 5) of the baseline fluorescent Ca 2ϩ signal 30 min after stimulation in the E 2 -BSA and P-BSA groups, which did not differ significantly. With the addition of 3 ng/ml of P-BSA, the intracellular Ca 2ϩ signal indicated by fluo 3 fluorescence immediately began to decrease and continued to decrease until reaching the basal Ca 2ϩ level (113 Ϯ 17% of basal) 25-30 min after P-BSA was added. The time required for the Ca 2ϩ signal to decay to one-half of the maximum value was 7 min (Fig. 4B) . A significant change in the intracellular Ca 2ϩ signal was not observed within 30 min after adding 333 pg/ml E 2 -BSA to a 5-HTϩU stimulated VMC (t 1/2 Ͼ 30 min; Fig. 4A ). PKC, which is thought to facilitate sustained increases in intracellular Ca 2ϩ in hyperreactive VMC (19) , was observed simultaneously with Ca 2ϩ by using the indicator hypericin. The relative abundance of PKC was represented by the whole cell average of the hypericin fluorescence (14) . In the primary cultured VMC from OVX monkeys, PKC levels increased to 133 Ϯ 18% and 144 Ϯ 21% of the prestimulated basal level 31 min after adding 5-HTϩU in two separate studies. With the addition of P-BSA, whole cell PKC average tended to increase, although the maximum level achieved (152 Ϯ 37%) was not significantly different from the PKC fluorescence intensity just before the addition of P-BSA (n ϭ 5). After the addition of E 2 -BSA, whole cell PKC fluorescence appeared to decrease to ϳ110-120% of the basal value but, as with P-BSA treatment, this difference did not achieve statistical significance at any time point after the addition of the steroid. Thus we observed no effect of either P-BSA or E 2 -BSA (brief stimulation with physiological concentrations) on 5-HTϩU-activated PKC in monkey coronary artery muscle cells.
DISCUSSION
The data reported herein suggest a rapid beneficial vasodilatory action of progesterone that has not previously been recognized as important in the coronary circulation. Direct vasorelaxation of constricted coronary arteries by the intracoronary administration of progesterone (100 ng) may be critical to understanding the cardiovascular benefits of ovarian steroid hormones used in hormone-replacement regimens.
In our experimental model, the phenomenon of ovarian steroid modulation of vascular reactivity characterized in nonhuman primates has been attributed (until now) to a genomic mechanism of action (5, 6, 14-16, 18, 19) . In this model, coronary artery focal constrictions with the characteristics of vasospasms are reliably induced pharmacologically in 12-yr-old nonatherosclerotic hypoestrogenic monkeys with 5-HTϩU. These focal constrictions are prevented when 17␤-estradiol, progesterone, or a combination of estradiol and progesterone are replaced in these OVX rhesus monkeys for 1, 2, or 4 wk. The in vivo protective effect of estrogen, progesterone, and the combination on coronary VMC reactivity in OVX rhesus monkeys correlates with 1) circulating ovarian steroid hormone levels, 2) intracellular Ca 2ϩ and PKC responses of VMCs dissociated from coronary arteries, and 3) expression of receptors for estrogen and progesterone in coronary artery cross sections taken from the same animals (16) . Treatment of OVX monkeys for 4 wk with physiological levels of progesterone (in the absence of added exogenous estrogen) also effectively eliminated the hyperreactivity of coronary arteries in vivo and the exaggerated and prolonged Ca 2ϩ responses of isolated VMC in vitro by reducing thromboxane A 2 -receptor density in arteries (15, 16) That a physiologically relevant level of progesterone can also reverse coronary vasospasm suggests a second, more rapid effect on the vessel wall. A small transient peripheral vasodilatory effect was observed in four of the six animals in which progesterone was injected into the coronary artery. However, vasodilatory actions for both the radiopaque contrast medium (Hexabrix) and the anesthetic agent employed (isoflurane) may have caused underestimation of the peripheral dilation by progesterone. Nevertheless, replacement of progesterone appears to prevent ovariectomyinduced coronary artery hyperreactivity by a genomic mechanism and to relax focal constrictions by a nongenomic mechanism. This benefit does not appear to be true for treatment with MPA, a commonly used synthetic progestin, which we and others have shown consistently negates the protective effects of estrogen on coronary reactivity in vivo (16, 18, 19, 27) .
These data strongly suggest the existence of an independent surface membrane progesterone receptor distinct from the classical nuclear progesterone receptor that is part of the transcription-activating super- family. Rapid vasodilation by progesterone poses powerful evidence of the existence of such a second progesterone mechanism. This study did not examine the effect of promiscuous progesterone-receptor blocker RU-486, as in vitro studies revealed this compound, by itself, affected intracellular Ca 2ϩ in VMC (Minshall and Hermsmeyer, unpublished observations). Our earlier studies have shown that, when progesterone or MPA are coexistent, MPA dominates, causing hyperreactivity despite the presence of physiological concentrations of estrogen and progesterone (16, 18, 19) . Surprisingly, a modest dose of progesterone injected into coronary arteries produced dilation, even in monkeys treated with MPA. In contrast, a prolonged vasodilatory action of progesterone was not observed in monkeys treated for 2 or more weeks with EPM (16, 18) , i.e., studies designed to test the transcriptional actions of 17␤-estradiol, progesterone, and MPA. Thus the directly observed angiographic dilation, and this action by progesterone superceding the hyperactive response expected in the MPA-treatment group, argues in favor of a separate mechanism of action.
Both immunohistochemical and physiological data suggest that the main site of action of progesterone is the VMC, with a lesser role for the endothelial cell. Thus we suspect that nonhuman primate coronary artery VMCs express a traditional ligand-inducible transcription factor, as well as a plasma membrane progesterone binding site (4). Our results suggest that membrane binding of progesterone rapidly modulates coronary artery diameter and can relieve focal constrictions (vasospasms) with nearly the same time course as the T-type Ca 2ϩ -channel blocker mibefradil, which is known to act on T-type Ca 2ϩ channels in the VMC membrane (17) . Our in vitro data reported herein also support the hypothesis that primary cultured coronary artery VMCs contain membrane progesterone binding sites capable of transducing a Ca 2ϩ -lowering effect within minutes.
Several reports of rapid actions of progesterone in a variety of tissue types indicate the existence of a membrane receptor. Progesterone acts on the plasma membrane of sperm, but in this case it increases intracellular Ca 2ϩ , which is thought to initiate the acrosome reaction (3). On human intestinal smooth muscle cells, Bielefeldt et al. (2) found that progesterone inhibits Ca 2ϩ signals consistent with blocking the L-type Ca 2ϩ channel. Both of these effects occurred very rapidly (within 1 min), were observed with supraphysiological levels of progesterone (0.1-50 g/ml), and were not blocked by antiprogestins, which prevent genomic actions of progesterone and other progestins (2, 3) . Whether the present observation of coronary vasodilation and VMC Ca 2ϩ suppression by progesterone can also be explained by this mechanism (progesterone blockade of L-type Ca 2ϩ channels) is not clear. Recently, a progesterone binding protein was isolated and cloned from porcine VMCs (4). The 1.9-kb transcripts shown by Northern analysis suggest that the protein is expressed in the liver Ͼ kidney Ͼ lung Ͼ cerebellum Ն heart (4). It is interesting to speculate that this membrane progesterone binding site leads to inhibition of Ca 2ϩ conductance via the L-type Ca 2ϩ channel. Synthetic progestins, such as MPA, do not appear to act at this nongenomic membrane binding site (3) . Thus it appears that a unique membrane progesterone binding site exists on sperm cells, intestinal cells, and VMCs. In each case, the functional significance is only beginning to be recognized. However, the evidence reported here suggests the rationale for more extensive investigation of this new-found beneficial role for progesterone. Taken together, the transcriptional actions on thromboxane A 2 -receptor expression (15) and the direct relaxant action on coronary arteries and isolated coronary VMCs appear to justify new interest in cardiovascular actions of progesterone. The rapid, nongenomic relaxant effect of progesterone suggested by both our in vivo and in vitro nonhuman primate analog of coronary artery reactivity provides evidence for a cardiovascular benefit of progesterone independent of classical genomic actions.
